Hematology and Oncology

EmailEmail    |   Bookmark Page Bookmark  |   RSS Feeds RSS  |   Print Page Print  

Ehab Atallah, MDEhab Atallah, MD

Best Doctors 2014 Ehab Atallah, MD

Associate Professor of Medicine




Ehab Atallah, MD, is Associate Professor of Medicine at the Medical College of Wisconsin Division of Hematology and Oncology, specializing in leukemia and myelodysplastic syndromes at Froedtert Hospital. He graduated from Cairo University School of Medicine in 1994, then completed an internal medicine residency in the Cleveland Clinic Health System and a fellowship in hematology/oncology at the Karmanos Cancer Center in Detroit, Michigan, where he also served as Chief Fellow. He then went on to complete a leukemia fellowship at M.D. Anderson Cancer Center in Houston, Texas. Dr. Atallah is board certified in Internal Medicine, Medical Oncology, and Hematology. He has authored numerous publications, including journal articles, meeting abstracts, and a book chapter. In 2007, he received the American Society of Clinical Oncology Foundation Merit Award. His current research interests are treatment of patients with chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, acute myelogenous leukemia, myeloproliferative neoplasms and myelodysplastic syndromes.

View our Clinical Trials

Selected Publications:

  1. Yan M, Geyer H, Mesa R, Atallah E, Callum J, Bartoszko J, Yee K, Maganti M,
    Wong F, Gupta V. Clinical Features of Patients With Philadelphia-Negative
    Myeloproliferative Neoplasms Complicated by Portal Hypertension. Clin Lymphoma
    Myeloma Leuk. 2014 Jun 11. pii: S2152-2650(14)00141-4. doi:
    10.1016/j.clml.2014.04.004. [Epub ahead of print] PubMed PMID: 25027569.
  2. Troy JD, Atallah E, Geyer JT, Saber W. Myelodysplastic syndromes in the United
    States: an update for clinicians. Ann Med. 2014 Apr 10. [Epub ahead of print]
    PubMed PMID: 24716735.
  3.  Atallah E, Bylow K, Troy J, Saber W. Treatment of older patients with
    high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic
    hematopoietic stem cell transplantation (Allo HSCT). Curr Hematol Malig Rep. 2014
    Mar;9(1):57-65. doi: 10.1007/s11899-013-0195-9. PubMed PMID: 24398726; PubMed
    Central PMCID: PMC4031643.
  4.  Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A,
    Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA. Management of
    cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of
    dose modifications on efficacy outcomes. Onco Targets Ther. 2013 Dec 17;7:13-21.
    doi: 10.2147/OTT.S53348. eCollection 2013. PubMed PMID: 24368888; PubMed Central
    PMCID: PMC3869911.
  5.  Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L,
    Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy
    PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson
    RA, Stock W, Odenike O. Phase II study of the oral MEK inhibitor selumetinib in
    advanced acute myelogenous leukemia: a University of Chicago phase II consortium
    trial. Clin Cancer Res. 2014 Jan 15;20(2):490-8. doi:
    10.1158/1078-0432.CCR-13-1311. Epub 2013 Oct 31. PubMed PMID: 24178622.
  6.  Kremyanskaya M, Atallah EL, Hoffman R, Mascarenhas JO. Clarifying the use of
    ruxolitinib in patients with myelofibrosis. Oncology (Williston Park). 2013
    Jul;27(7):706-14. Review. Erratum in: Oncology (Williston Park). 2013
    Aug;27(8):737. PubMed PMID: 23977767.
  7.  Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, Maziarz RT,
    Cortes J, Kalaycio ME, Horowitz MM. Impact of donor source on hematopoietic cell
    transplantation outcomes for patients with myelodysplastic syndromes (MDS).
    Blood. 2013 Sep 12;122(11):1974-82. doi: 10.1182/blood-2013-04-496778. Epub 2013
    Jul 11. PubMed PMID: 23847196; PubMed Central PMCID: PMC3772501.
  8.  Atallah E, Verstovsek S. Emerging drugs for myelofibrosis. Expert Opin Emerg
    Drugs. 2012 Dec;17(4):555-70. doi: 10.1517/14728214.2012.748748. Review. PubMed
    PMID: 23186315.
  9.  Randhawa J, Wong S, Atallah E, Olasz E. Clinical regression of squamous cell
    carcinoma and keratoacanthomas in a patient treated with a hypomethylating agent.
    Int J Dermatol. 2014 Jan;53(1):e13-4. doi: 10.1111/j.1365-4632.2011.05350.x. Epub
    2012 Sep 24. PubMed PMID: 22998756.
  10.  Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S. Splenomegaly in
    myelofibrosis--new options for therapy and the therapeutic potential of Janus
    kinase 2 inhibitors. J Hematol Oncol. 2012 Aug 1;5:43. doi:
    10.1186/1756-8722-5-43. Review. PubMed PMID: 22852872; PubMed Central PMCID:
  11.  Kim J, Haddad RY, Atallah E. Myeloproliferative neoplasms. Dis Mon. 2012
    Apr;58(4):177-94. doi: 10.1016/j.disamonth.2012.01.002. Review. PubMed PMID:
  12.  Torgerson SR, Haddad RY, Atallah E. Chronic myelogenous leukemia for primary
    care physicians. Dis Mon. 2012 Apr;58(4):168-76. doi:
  13.  Atallah E. Nilotinib cardiac toxicity: should we still be concerned? Leuk
    Res. 2011 May;35(5):577-8. doi: 10.1016/j.leukres.2011.01.021. Epub 2011 Feb 17.
    PubMed PMID: 21333353.
  14.  Atallah E, Abrams J, Ayash L, Bentley G, Abidi M, Ratanatharathorn V, Uberti
    J. Long term follow-up of allogeneic stem cell transplantation in patients with
    myelodysplastic syndromes using busulfan, cytosine arabinoside, and
    cyclophosphamide. Am J Hematol. 2010 Aug;85(8):579-83. doi: 10.1002/ajh.21761.
    PubMed PMID: 20578198; PubMed Central PMCID: PMC3800118.
  15.  Angel JR, Parker S, Sells RE, Atallah E. Recurrent deep vein thrombosis and
    pulmonary embolism in a young man with Klinefelter's syndrome and heterozygous
    mutation of MTHFR-677C>T and 1298A>C. Blood Coagul Fibrinolysis. 2010
    Jun;21(4):372-5. PubMed PMID: 20449891.

View more publications by Dr. Atallah (PubMed)

Best Doctors® logo is registered trademark of Best Doctors, Inc. in the United States and other countries.
© 2014 Medical College of Wisconsin
Page Updated 11/04/2014